Preimplantation Genetic Testing Market

Global Preimplantation Genetic Testing Market Size

The global preimplantation genetic testing market was worth US$ 695 million in 2025 and is anticipated to reach a valuation of US$ 1,943 million by 2034, from US$ 779.10 million in 2026, and it is predicted to register a CAGR of 12.1% during the forecast period 2026 to 2034.

Preimplantation genetic testing is a diagnostic procedure utilized during in vitro fertilization cycles to assess embryos for specific genetic abnormalities before uterine transfer. This advanced reproductive technology encompasses preimplantation genetic testing for aneuploidy, monogenic disorders, and structural rearrangements by enabling clinicians to select chromosomally normal embryos for implantation. The clinical application of this technology has expanded significantly beyond rare Mendelian disorders to include screening for age-related chromosomal errors that contribute to miscarriage and implantation failure. The utilization of preimplantation genetic testing has increased by over 15% annually in the United States due to improved accuracy and reduced costs, as per the study. The technology requires specialized laboratory infrastructure, including next-generation sequencing platforms and skilled embryologists capable of performing trophectoderm biopsy with minimal impact on embryo viability. As per guidelines from international reproductive health organizations, the procedure is increasingly recommended for patients with recurrent pregnancy loss or known carrier status for genetic conditions. The integration of artificial intelligence in embryo selection further enhances the precision of this diagnostic modality.

MARKET DRIVERS

Rising maternal age and delayed childbearing drive demand for genetic screening

The global trend towards delayed childbearing for increased adoption of preimplantation genetic testing in assisted reproductive technologies is fuelling the growth of the preimplantation genetic testing market. Women who conceive after age 35 face significantly higher risks of chromosomal abnormalities, such as trisomy 21, trisomy 18, and trisomy 13, due to age-related declines in oocyte quality. According to the Centers for Disease Control and Prevention, the birth rate for women aged 35 to 39 years has increased by 67% over the past two decades, while rates for women aged 40 to 44 years have doubled. Advanced maternal age is associated with a miscarriage rate exceeding 50% in natural conceptions, creating an urgent need for interventions that improve pregnancy success, as per the study. Preimplantation genetic testing for aneuploidy allows clinicians to identify and transfer only chromosomally normal embryos, thereby reducing the risk of miscarriage and increasing the likelihood of a healthy live birth. Clinical studies indicate that women over 40 years who undergo genetic screening achieve live birth rates comparable to those of younger women using unscreened embryos. The psychological burden of repeated pregnancy losses motivates many older couples to invest in comprehensive genetic evaluation before embryo transfer. Healthcare providers increasingly recommend screening for patients over 38 years, recognizing its potential to reduce time to pregnancy and minimize emotional distress.

Increasing prevalence of inherited genetic disorders fuels testing adoption

The growing awareness and diagnosis of monogenic disorders is another factor boosting the growth of the preimplantation genetic testing market. Couples who are known carriers of serious genetic conditions such as cystic fibrosis, spinal muscular atrophy, and Huntington disease seek preimplantation genetic testing for monogenic disorders to prevent transmission to their offspring. The expansion of carrier screening panels, which now test for over 100 genetic conditions, has identified millions of asymptomatic carriers who were previously unaware of their risk. The American College of Medical Genetics and Genomics recommends universal carrier screening for several common recessive conditions, leading to earlier identification of at risk couples. Preimplantation genetic testing offers these individuals the opportunity to have biological children without the fear of passing on debilitating diseases. Clinical data demonstrates that this approach achieves pregnancy rates similar to standard in vitro fertilization while virtually eliminating the risk of affected births. Patient advocacy groups actively promote education about reproductive options for carriers, driving referrals to fertility specialists. Insurance coverage for genetic testing is expanding in several regions, reducing financial barriers for families with known genetic histories.

MARKET RESTRAINTS

High procedural costs and limited insurance coverage restrict accessibility

The substantial financial burden across diverse socioeconomic groups is hindering the growth of the preimplantation genetic testing market. According to the study, out-of-pocket expenses for genetic screening can add 3000 to 5000 dollars to the base cost of an in vitro fertilization cycle. Many insurance providers classify preimplantation genetic testing as experimental or elective, excluding it from coverage policies even when medically indicated for preventing serious genetic diseases. This lack of financial support limits access to affluent demographics, creating disparities in reproductive healthcare equity. Patients often face difficult decisions regarding how many embryos to test due to cost constraints, potentially compromising the effectiveness of the selection process. The high cost also discourages younger patients with lower risk profiles from opting for screening, despite potential long-term benefits. Healthcare systems in developing nations rarely subsidize these advanced procedures, leaving them accessible only to a small elite population.

Ethical concerns and regulatory restrictions hinder market expansion

The ethical controversies surrounding embryo selection and genetic manipulation is another factor impeding the growth of preimplantation genetic testing. Religious and philosophical groups argue that discarding embryos identified as abnormal constitutes unethical destruction of potential life, leading to strict regulatory frameworks in certain countries. According to the study, several European nations, including Germany and Italy, impose stringent limitations on the number of embryos that can be created or tested by effectively restricting the utility of preimplantation genetic screening. The Council of Europe Convention on Human Rights and Biomedicine prohibits sex selection for non-medical reasons by limiting the scope of testing in signatory countries. Fear of a slippery slope towards designer babies influences policymakers to maintain cautious regulatory stances. Legal uncertainties regarding the status of embryos complicate consent processes and liability issues for clinics. Some jurisdictions require extensive ethical review board approvals for each case involving monogenic disorder testing, delaying treatment timelines. These ethical and legal complexities create an unpredictable operating environment for providers, discouraging investment in some regions.

MARKET OPPORTUNITIES

Integration of artificial intelligence enhances embryo selection accuracy

The incorporation of artificial intelligence and machine learning algorithms for improving diagnostic precision and clinical outcomes is setting up new opportunities for the growth of the preimplantation genetic testing market. Advanced computational models can analyze complex genomic data alongside morphological images of embryos to predict implantation potential with greater accuracy than traditional methods. According to research, AI-driven analysis reduces the error rate in aneuploidy detection by up to 15% compared to manual interpretation by embryologists. Machine learning platforms can process vast datasets from previous cycles to identify subtle patterns associated with successful pregnancies, refining selection criteria over time. The European Society of Human Reproduction and Embryology notes that AI tools assist in prioritizing embryos for biopsy, optimizing laboratory efficiency and reducing handling stress on viable specimens. Automated image recognition systems provide objective assessments of embryo development stages, minimizing subjective variability among different technicians. The integration of these digital tools with electronic health records facilitates longitudinal tracking of patient outcomes, enabling continuous improvement of protocols. Fertility clinics leveraging AI report higher confidence in single embryo transfer decisions, reducing the risk of multiple gestations. Pharmaceutical and technology companies are collaborating to develop proprietary algorithms that offer competitive advantages in the market. These technological advancements position preimplantation genetic testing as a data-driven precision medicine service by attracting investment and enhancing clinical value propositions.

Expansion into polygenic risk scoring creates new clinical applications

The emerging application of polygenic risk scoring for expanding the scope of reproductive genetics beyond single-gene disorders is another attribute to escalate the growth of the preimplantation genetic testing market. Polygenic risk scores estimate the likelihood of developing complex conditions such as diabetes, heart disease, and schizophrenia based on the cumulative effect of thousands of genetic variants. According to recent studies, polygenic scoring can identify embryos with significantly lower risks for common chronic diseases, offering parents additional information for decision-making. This technology appeals to individuals with strong family histories of multifactorial conditions who seek to minimize health risks for their future children. The American Society of Human Genetics acknowledges the potential clinical utility of polygenic scores, while emphasizing the need for rigorous validation and ethical oversight. Direct-to-consumer genetic testing companies are partnering with fertility clinics to offer integrated screening packages that include polygenic assessments. Regulatory bodies in some regions are beginning to evaluate frameworks for overseeing these advanced applications, potentially opening pathways for formal clinical adoption. The ability to provide comprehensive risk profiles for multiple conditions enhances the perceived value of preimplantation testing. As scientific understanding of polygenic architecture improves, the accuracy and relevance of these scores will increase, driving demand among informed patients.

MARKET CHALLENGES

Risk of mosaicism and diagnostic errors complicates clinical decision-making

The presence of chromosomal mosaicism in embryos is acting as a barrier for the growth of the preimplantation genetic testing market. Mosaicism occurs when an embryo contains both normal and abnormal cells, leading to potential discrepancies between the biopsied trophectoderm cells and the inner cell mass that forms the fetus. Discarding mosaic embryos may result in the loss of viable candidates capable of self-correction and healthy development, while transferring them carries risks of miscarriage or congenital anomalies. Clinicians face difficult ethical and medical decisions when counseling patients about mosaic results, as long-term outcome data remains limited. False positive and false negative rates, although low, can lead to the transfer of abnormal embryos or the discard of healthy ones, undermining patient trust. The technical limitations of current sequencing technologies in detecting low-level mosaicism further complicate diagnostic reliability. Standardized guidelines for reporting and managing mosaic findings are still evolving, leading to variability in practice across different clinics. Patients often experience significant anxiety when confronted with ambiguous results, requiring extensive psychological support.

Lack of standardized regulations and quality control varies global practices

The absence of universally accepted regulatory standards and quality control measures is additionally impeding the growth of the preimplantation genetic testing market. Different countries employ varying criteria for laboratory accreditation, personnel certification, and testing protocols, leading to inconsistent performance metrics. The success rates and error rates for preimplantation genetic testing vary significantly between regions with strict oversight and those with minimal regulation. The lack of harmonized standards complicates cross-border reproductive care, as patients may struggle to verify the credibility of foreign clinics. Some laboratories utilize outdated sequencing technologies or insufficient validation processes, increasing the risk of misdiagnosis. The need for global guidelines to ensure equitable and safe access to assisted reproductive technologies. Professional societies attempt to fill this gap through voluntary best practice recommendations, but adherence is not mandatory. Variability in biopsy techniques, culture conditions, and genetic analysis platforms further contributes to outcome disparities. Patients may unknowingly receive substandard care in unregulated markets, facing higher risks of failed cycles or incorrect diagnoses. Establishing international accreditation bodies and standardized reporting frameworks remains a complex logistical and political challenge. These regulatory gaps undermine confidence in the technology and hinder the development of a cohesive global market for preimplantation genetic testing services.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Procedure Type Insights

The preimplantation genetic screening segment was the largest by accounting for 34.8% of the preimplantation genetic testing market share in 2025, with its broad applicability in improving in vitro fertilization success rates for a wide patient demographic. Unlike diagnostic testing, which targets specific known mutations, screening identifies chromosomal aneuploidies that are common causes of implantation failure and miscarriage, particularly in women of advanced maternal age. The procedure is increasingly viewed as a standard of care for elective single embryo transfer protocols, reducing the risks associated with multiple gestations. The widespread availability of next-generation sequencing platforms has reduced the cost per sample by making screening accessible to a larger patient base. Fertility clinics promote screening as a tool to reduce time to pregnancy and emotional distress associated with recurrent loss. The non-specific nature of screening allows it to be applied to patients without known genetic histories, significantly boosting market growth.

The preimplantation genetic diagnosis segment is expected to register the fastest CAGR of 14.2% throughout the forecast period. The growth of the segment is driven by the increasing prevalence of known monogenic disorders and the expanding availability of carrier screening panels. As genetic testing becomes more routine in preconception care, more couples are identified as carriers for serious recessive conditions such as cystic fibrosis, spinal muscular atrophy, and Tay-Sachs disease. Preimplantation genetic diagnosis allows these couples to avoid terminating affected pregnancies by selecting unaffected embryos before implantation. The ethical preference for prevention over termination drives demand among religious and conservative demographics. Advances in multiplex polymerase chain reaction and next-generation sequencing have reduced the cost and complexity of diagnosing single-gene disorders by making the procedure more accessible. Regulatory approvals for new diagnostic kits streamline laboratory workflows, enabling faster turnaround times. Patient advocacy groups for specific genetic diseases actively promote awareness of reproductive options, driving referrals to specialized fertility centers.

By Technology Insights

The next-generation sequencing segment was the largest by holding 44.7% of the preimplantation genetic testing market share in 2025 due to its superior accuracy, comprehensive genomic coverage, and ability to detect a wide range of chromosomal abnormalities. Next-generation sequencing achieves accuracy rates exceeding 98% in detecting aneuploidies, significantly outperforming older technologies like fluorescence in situ hybridization, as per research. The high throughput capability of next-generation sequencing platforms enables laboratories to process large volumes of samples efficiently, reducing turnaround times to under 24 hours in some facilities. The cost per sample has decreased substantially due to economies of scale and technological improvements, making it the preferred choice for high-volume fertility clinics. The ability to detect low-level mosaicism with greater precision enhances clinical decision-making, although interpretation remains complex. Major diagnostic companies have developed standardized kits specifically optimized for preimplantation testing, ensuring consistent performance across different laboratories.

The single nucleotide polymorphism arrays segment is significantly growing at an anticipated CAGR of 13.5% from 2026 to 2034, with the unique ability of SNP arrays to detect not only aneuploidies but also uniparental disomy and contamination from parental DNA. SNP technology provides additional information about the inheritance pattern of chromosomes, which is used for identifying meiotic errors. This capability is particularly valuable for patients undergoing preimplantation genetic diagnosis for monogenic disorders, as it allows for haplotype mapping without requiring prior knowledge of the specific mutation in some cases. The technology also helps identify sample mix-ups or contamination, enhancing laboratory safety and reliability. Recent advancements have improved the resolution of SNP arrays by allowing for the detection of smaller copy number variations. The decreasing cost of SNP chips makes them increasingly competitive with next-generation sequencing for specific applications. Fertility clinics appreciate the robustness of SNP data in complex cases involving structural rearrangements.

By Application Insights

The aneuploidy screening segment accounted for 32.3% of the preimplantation genetic testing market share in 2025 due to the high prevalence of chromosomal errors in human embryos and their direct impact on reproductive success. Aneuploidy, the presence of an abnormal number of chromosomes, is the leading cause of implantation failure and early miscarriage. Screening for these abnormalities allows clinicians to select euploid embryos, which is significantly improving live birth rates per transfer. The application is relevant to a broad patient population, including those with advanced maternal age, recurrent miscarriage, and repeated in vitro fertilization failure. Clinical guidelines increasingly support aneuploidy screening as a tool to optimize outcomes in these groups. The widespread acceptance of this application by reproductive endocrinologists drives consistent demand for testing services. The ability to reduce the time to pregnancy and minimize the emotional toll of multiple failed cycles further reinforces its popularity.

The single-gene disorders are likely to exhibit the fastest CAGR of 15.0% from 2026 to 2034, with the increasing availability of carrier screening and the desire of at-risk couples to prevent the transmission of serious genetic diseases. Conditions such as cystic fibrosis, beta thalassemia, and Huntington disease have well-established diagnostic protocols, making them ideal candidates for preimplantation testing. According to the study, millions of individuals worldwide are carriers for severe recessive disorders, creating a great latent demand for preventive reproductive services. Advances in molecular diagnostics have simplified the process of developing custom probes for specific family mutations by reducing turnaround time and cost. Patient advocacy groups play a crucial role in raising awareness and supporting families through the testing process. The ethical imperative to prevent suffering from debilitating genetic conditions drives strong patient commitment to this application. Insurance coverage for medically necessary genetic testing is expanding, further facilitating access.

By End Users Insights

The maternity centres and fertility clinics segment held a significant share of the preimplantation genetic testing market in 2025. These facilities are the primary point of contact for patients undergoing in vitro fertilization and are responsible for embryo biopsy and coordination with genetic laboratories. According to some data reports, the majority of preimplantation testing orders originate directly from fertility specialists who integrate testing into their treatment protocols. The close relationship between clinicians and patients allows for personalized counseling and timely decision-making regarding embryo transfer. Fertility clinics benefit from offering integrated services that include genetic testing, enhancing their competitive advantage and patient retention. The high volume of in vitro fertilization cycles performed in these centers ensures a steady stream of samples for testing. Many large fertility networks have established partnerships with specific genetic laboratories to streamline logistics and ensure quality control.

The hospitals and diagnostic laboratories segment is likely to grow at the fastest CAGR of 9.2% from 2026 to 2034, where fertility treatments are integrated into general healthcare systems. Large hospital networks with dedicated reproductive medicine departments utilize internal diagnostic labs for genetic testing, ensuring tight quality control and data security. The hospital-based labs are increasingly offering preimplantation testing services to capture revenue from high-margin genetic diagnostics. The presence of multidisciplinary teams including geneticists, obstetricians, and neonatologists in hospitals facilitates comprehensive care for high-risk pregnancies identified through testing. Diagnostic laboratories benefit from economies of scale, processing samples from multiple fertility clinics and hospitals. The trend towards centralization of specialized testing in large reference labs supports this segment growth. Government-funded healthcare systems often prefer hospital-based providers for regulated genetic services.

REGIONAL ANALYSIS

North America Preimplantation Genetic Testing Market Analysis

North America was the largest contributor by accounting for 40.2% of the preimplantation genetic testing market share in 2025 through high healthcare expenditure, advanced fertility infrastructure, and favorable regulatory environments for genetic innovation. The presence of major genetic testing companies and research institutions fosters continuous technological advancement. High awareness of genetic diseases and carrier status among the population drives demand for preventive testing. Private insurance coverage for infertility and genetic testing is expanding by improving accessibility for middle-income patients. The legal framework in the US permits a wide range of genetic testing applications, including sex selection for family balancing, which is restricted in other regions. Strong patient advocacy groups and professional societies promote education and best practices.

Europe Preimplantation Genetic Testing Market Analysis

Europe preimplantation genetic testing market was ranked second, holding 30.3% of the share in 2025, with diverse regulatory frameworks, with countries like the United Kingdom and Spain having well-established and supportive legal environments for genetic testing. According to the European Society of Human Reproduction and Embryology, Europe performs a significant number of preimplantation genetic diagnosis cycles for monogenic disorders due to strong public health support for preventing severe genetic diseases. National health services in several countries cover testing for specific medical indications, ensuring equitable access. The region is a hub for clinical research and guideline development, influencing global standards. However, restrictive laws in countries like Germany and Italy limit market growth in those areas. The aging population in Western Europe increases the prevalence of age-related infertility, driving demand for screening. Cross-border reproductive care allows patients from restrictive countries to access services in more permissive neighbors, sustaining overall regional volume.

Asia Pacific Preimplantation Genetic Testing Market Analysis

The Asia Pacific preimplantation genetic testing market is expected to grow at the fastest CAGR during the forecast period. China, India, Japan, and Australia drive this growth through rising disposable incomes, increasing awareness of genetic health, and growing medical tourism. According to data, the number of in vitro fertilization cycles in Asia has doubled in the past five years, creating a large base for testing adoption. Governments in countries like China are investing in genetic research and infrastructure to address population health challenges. The rising prevalence of thalassemia and other genetic disorders in South Asia drives demand for diagnostic testing. Medical tourism hubs in Thailand and India attract international patients seeking affordable and high-quality genetic testing services. Local manufacturing of testing kits is reducing costs and improving availability. Cultural shifts towards smaller families and delayed childbearing increase the value placed on ensuring the health of each child.

Latin America Preimplantation Genetic Testing Market Analysis

Latin America preimplantation genetic testing market growth is driven by improving healthcare infrastructure in major economies. Brazil and Mexico are the largest contributors in this region, with advanced reproductive services to affluent patients, while public systems face resource constraints. Increasing awareness of genetic diseases and carrier screening is driving demand among educated urban populations. Regulatory frameworks are evolving to accommodate genetic technologies, though variability remains. Economic challenges and currency fluctuations impact affordability, limiting mass market penetration. However, long-term trends indicate growing interest in preventive genetic medicine. Local partnerships with international testing providers improve service quality and access.

Middle East and Africa Preimplantation Genetic Testing Market Analysis

The Middle East and Africa preimplantation genetic testing market is likely to grow with the high prevalence of consanguinity-related genetic disorders. Gulf Cooperation Council countries, including Saudi Arabia and the United Arab Emirates, lead in adoption by leveraging substantial healthcare investments to build specialized genetic centers. According to the study, high rates of autosomal recessive disorders drive strong demand for preimplantation genetic diagnosis. Government initiatives promote genetic counseling and screening to reduce the burden of inherited diseases. In Africa, access remains limited to private clinics in South Africa and Kenya, serving small elite populations. Cultural and religious factors influence acceptance of genetic testing, with varying degrees of support across different communities. International collaborations aim to build local capacity and reduce costs.

COMPETITIVE LANDSCAPE

The competitive landscape of the preimplantation genetic testing market features established diagnostic giants and specialized biotechnology firms competing through technological superiority and clinical validation. Market participants differentiate themselves by offering superior accuracy, faster turnaround times, and comprehensive genomic coverage in their testing panels. The barrier to entry remains high due to stringent regulatory requirements for medical device approval and the need for extensive clinical data to prove efficacy. Companies engage in aggressive marketing campaigns targeting reproductive endocrinologists and embryologists to establish brand loyalty and preference among key decision-makers. Collaboration with academic institutions for research and development helps companies stay at the forefront of scientific advancements. Intellectual property protection plays a vital role as firms secure patents for novel sequencing methods and bioinformatics algorithms. Service quality and technical support become differentiators, as laboratories rely on consistent performance for clinical decision-making.

KEY MARKET PLAYERS

Some of the promising companies operating in the global preimplantation genetic testing market profiled in the report are

• Illumina Inc.
• Yikon Genomics
• CooperSurgical
• Oxford Gene Technology, Inc.
• Thermo Fisher Scientific, Inc.
• Rubicon Genomics, Inc.
• Agilent Technologies, Inc.
• Natera, Inc.
• Abbott Laboratories
• PerkinElmer, Inc.
• SciGene Corporation

TOP PLAYERS IN THE MARKET

• CooperSurgical Inc. stands as a prominent leader in the preimplantation genetic testing market through its comprehensive portfolio of reproductive health solutions and diagnostic technologies. The company provides integrated systems that combine embryo biopsy tools with advanced genetic screening platforms to streamline laboratory workflows. CooperSurgical recently expanded its next-generation sequencing capabilities to offer faster turnaround times and higher accuracy for aneuploidy detection. Their strategic partnerships with fertility clinics globally ensure widespread adoption of their standardized protocols and consumables. The company actively invests in research and development to enhance the sensitivity of their assays for detecting mosaicism and structural rearrangements. CooperSurgical emphasizes education and training programs for embryologists and geneticists to ensure optimal utilization of their technologies. These initiatives reinforce their reputation as a trusted partner in assisted reproductive technology and genetic diagnostics worldwide.
• Illumina Inc. contributes significantly to the preimplantation genetic testing market by providing high-throughput next-generation sequencing platforms that serve as the backbone for many diagnostic laboratories. The company offers specialized kits and bioinformatics software designed specifically for preimplantation genetic screening and diagnosis applications. Illumina recently launched updated sequencing reagents that reduce costs per sample while improving data quality and coverage uniformity. Their focus on scalability allows large reference laboratories to process thousands of samples efficiently, supporting the growing demand for genetic testing. The company collaborates with key opinion leaders to validate clinical utility and establish best practices for data interpretation. Illumina also prioritizes regulatory compliance across multiple jurisdictions to facilitate global market access. These technological advancements and strategic collaborations strengthen their position as a critical enabler of modern preimplantation genetic testing services.
• Thermo Fisher Scientific Inc. is a key player in the preimplantation genetic testing market, offering robust polymerase chain reaction and next-generation sequencing solutions tailored for reproductive genetics. The company provides end-to-end workflows including sample preparation, amplification, and analysis tools that ensure consistent and reliable results. Thermo Fisher recently introduced automated liquid handling systems that minimize human error and increase laboratory throughput for high-volume testing centers. Their commitment to innovation drives the development of multiplex assays capable of detecting single gene disorders and aneuploidies simultaneously. The company supports customers with extensive technical resources and custom assay design services for rare genetic conditions. Thermo Fisher leverages its global distribution network to ensure timely availability of critical reagents and instruments. These efforts demonstrate their dedication to advancing precision medicine in reproductive healthcare and strengthening their market presence.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Key players in the preimplantation genetic testing market primarily focus on technological innovation and workflow integration to maintain competitive advantages. Companies invest heavily in developing next-generation sequencing platforms with higher throughput and lower costs to make testing more accessible. Strategic partnerships with fertility clinics and reference laboratories enable firms to create seamless end-to-end service models. Expansion into emerging markets represents another crucial strategy as companies seek to capitalize on growing awareness of genetic health in Asia Pacific and Latin America. Manufacturers prioritize regulatory approvals in multiple jurisdictions to ensure broad market access and compliance with international standards. Training and education initiatives form an integral part of corporate strategies to address the complexity of genetic interpretation and improve clinical adoption. Mergers and acquisitions allow larger corporations to integrate complementary technologies and expand their product portfolios comprehensively. Digital health integration, including artificial intelligence for data analysis, serves as a differentiating factor for leading market participants seeking to improve diagnostic accuracy.

MARKET SEGMENTATION

This research report on the global preimplantation genetic testing market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2033.

By Procedure Type

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Validation Biomarkers
• Fluorescence in Situ Hybridization
• Comparative Genomic Hybridization
• Single-Nucleotide Polymorphism

By Product and Service

• Reagents and Consumables
• Instruments
• Software and Services

By Application

• Aneuploidy
• Structural Chromosomal Abnormalities
• Single Gene Disorders
• X-Linked Disorders
• HLA Typing

By End-users

• Maternity Centres & Fertility Clinics
• Hospitals, Diagnostic Labs, and Service Providers
• Research Laboratories & Academic Institutes

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa